| Schedule of investment in Hepalys is accounted for using the equity method of accounting |
| | | | | | | | | | December 31, | | December 31, | | December 31, | | (in thousands of euros) | | 2023 | | 2024 | | 2025 | | Intangible assets | | 20,278 | | 16,984 | | 12,729 | | Total non-current assets | | 20,278 | | 16,984 | | 12,729 | | Other current assets | | 44 | | 81 | | 102 | | Cash and cash equivalents | | 1,082 | | 1,785 | | 81 | | Total current assets | | 1,126 | | 1,866 | | 183 | | Deferred assets | | 41 | | 2 | | — | | Total assets | | 21,444 | | 18,851 | | 12,912 | | | | | | | | | | Capital stock | | 640 | | 552 | | 489 | | Capital reserve | | 22,655 | | 21,489 | | 8,267 | | Capital surplus-others | | — | | 816 | | 10,259 | | Earnings brought forward | | (178) | | (1,089) | | (2,745) | | Net loss for the period | | (1,111) | | (3,277) | | (3,504) | | Treasury Shares | | (812) | | — | | — | | Shareholders’ equity | | 21,194 | | 18,490 | | 12,766 | | Trade payables | | 237 | | 353 | | 134 | | Other current liabilities | | 13 | | 8 | | 12 | | Total current liabilities | | 250 | | 361 | | 146 | | Total equity and liabilities | | 21,444 | | 18,851 | | 12,912 | | | | | | | | | | Opening net assets | | 22,645 | | 21,122 | | 18,368 | | Loss for the period(1) | | (879) | | (3,277) | | (3,816) | | Other comprehensive income | | 247 | | (920) | | (1,786) | | Capital variations | | (819) | | 1,566 | | — | | Closing net assets | | 21,194 | | 18,490 | | 12,766 | | | | | | | | | | Group’s share in % | | 15 | % | 15 | % | 15 | % | (in thousands of euros) | | | | | | | | Group’s share | | 3,267 | | 2,707 | | 1,869 | | Elimination of unrealized profit on downstream sales | | (1,881) | | (1,604) | | (1,378) | | Goodwill | | 38 | | 37 | | 37 | | Carrying amount | | 1,425 | | 1,139 | | 527 | |
(1)Refer to Note 23 – Share of net profit (loss) - equity method
|